Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + decitabine
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tislelizumab + decitabine is a combination therapy being evaluated for the treatment of relapsed or refractory classic Hodgkin lymphoma (cHL). Tislelizumab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. It is specifically engineered to minimize binding to Fcγ receptors on macrophages, thereby preventing antibody-dependent cellular phagocytosis (ADCP), a mechanism that can limit the efficacy of anti-PD-1 antibodies. Decitabine is a hypomethylating agent that inhibits DNA methyltransferase, leading to the reactivation of epigenetically silenced genes. In the context of classic Hodgkin lymphoma, decitabine is hypothesized to enhance the immunogenicity of tumor cells and sensitize them to PD-1 blockade. This regimen is being investigated by the Institute of Hematology & Blood Diseases Hospital in China as a second-line salvage therapy, often followed by autologous stem cell transplantation (ASCT) consolidation.
- Other names
- tislelizumabdecitabinePD-1 inhibitor combined with decitabinePD1 inhibitor combined with decitabinePD 1 inhibitor combined with decitabine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + decitabine.